Justin A. Renz

CIK: 0001466562

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)4 (66.7%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (33.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

ZVRA

ZEVRA THERAPEUTICS, INC.

Officer

ARDX

ARDELYX, INC.

Officer

Discretionary Trading P&L

Holdings

Transaction History (6 total)

ZVRA
ZEVRA THERAPEUTICS, INC.
Mar 18, 2026
Award(A)
Stock Option (right to buy)
Direct
300K shares-
ARDX
ARDELYX, INC.
Aug 21, 2025
Sale(S)
Direct
7K shares at avg. $5.93$42K
ARDX
ARDELYX, INC.
May 20, 2025
Sale(S)
Direct
7.2K shares at avg. $4.08$29K
ARDX
ARDELYX, INC.
Feb 25, 2025
Award(A)
Direct
136.7K shares-
ARDX
ARDELYX, INC.
Feb 20, 2025
Sale(S)
Direct
5.2K shares at avg. $5.62$29K
ARDX
ARDELYX, INC.
Nov 20, 2024
Sale(S)
Direct
5.3K shares at avg. $4.79$25K

		Type	Shares	Price		Ownership
Mar 18, 2026	ZVRA ZEVRA THERAPEUTICS, INC.	Award(A) Stock Option (right to buy)	300,000	-	-	Direct
Aug 21, 2025	ARDX ARDELYX, INC.	Sale(S)	7,037	$5.93	$41,741	Direct
May 20, 2025	ARDX ARDELYX, INC.	Sale(S)	7,218	$4.08	$29,460	Direct
Feb 25, 2025	ARDX ARDELYX, INC.	Award(A)	136,680	-	-	Direct
Feb 20, 2025	ARDX ARDELYX, INC.	Sale(S)	5,171	$5.62	$29,077	Direct
Nov 20, 2024	ARDX ARDELYX, INC.	Sale(S)	5,260	$4.79	$25,219	Direct

1-6 of 6 transactions

About Renz Justin A

Renz Justin A (SEC CIK 0001466562) files insider reports with the SEC as CFO of ZEVRA THERAPEUTICS, INC. (ZVRA) and Chief Financial Officer of ARDELYX, INC. (ARDX).

Signal8 holds 7 ownership filings by Renz Justin A (1 Form 3, 6 Form 4), filed between Nov 22, 2024 and Mar 19, 2026. Those filings report 6 transactions, from Nov 20, 2024 to Mar 18, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Renz Justin A's filings is in BOSTON, MA.

Recent filings by Renz Justin A

Mar 18, 2026: Grant or award of ZVRA derivative securities (Form 4, code A).
Aug 21, 2025: Open-market sale of ARDX shares (Form 4, code S).
May 20, 2025: Open-market sale of ARDX shares (Form 4, code S).
Feb 25, 2025: Grant or award of ARDX shares (Form 4, code A).
Feb 20, 2025: Open-market sale of ARDX shares (Form 4, code S).

Other insiders filing for ZEVRA THERAPEUTICS, INC. (ZVRA)

McFarlane Neil F., President and CEO
Thompson Rahsaan, Chief Legal & Compliance
Watton Corey Michael, Director
FAVORITO TAMARA A, Director
Secor Alicia, Director
Calder Douglas W, Director

How to read Form 4 transaction codes